New treatments for Alzheimer’s disease
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p1852 (Published 22 August 2023) Cite this as: BMJ 2023;382:p1852- Robert Howard, professor of old age psychiatry,
- Helen C Kales, Joe P Tupin, chair of psychiatry 2
- 1University College London, London, UK
- 2University of California, Davis, California, USA
- Correspondence to: H C Kales: hckales{at}ucdavis.edu
Donanemab is a new monoclonal antibody treatment that binds to amyloid β to stimulate microglial removal of amyloid plaques from the brain in people with Alzheimer’s disease.1 In the recently published Trailblazer-ALZ 2 trial in 1736 adults with early symptomatic disease, participants treated with donanemab had a mean decline over 18 months that was 3.03 points less than those given placebo on a 144 point scale of cognition and functional ability (integrated Alzheimer disease rating scale (−6.02 v −9.27; difference 3.25, 95% confidence interval 1.88 to 4.62). All participants had evidence of brain amyloid and tau protein accumulation on positron emission tomography at recruitment.2 Of a further 24 secondary and exploratory trial outcomes, 23 showed statistically significant benefits with donanemab. Notably, the benefit on the mini-mental state examination was 0.48 points; patients with Alzheimer’s disease dementia typically show an annual decline of 3 points on this measure.3
The …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.